OXFORD, England--(BUSINESS WIRE)--ProImmune Ltd., a leader in services for understanding immune responses, announced today the commercial launch of ProStorm™, an in vitro cytokine release assay, which can help assess the likelihood of first infusion reactions to novel therapeutics. ProStorm™ offers drug developers an improved route to risk identification prior to initiating clinical trials in man.
